LncRNA MEG3 overexpression inhibits the development of diabetic retinopathy by regulating TGF‑β1 and VEGF

Zhang,Daning; Qin,Haixiang; Leng,Ying; Li,Xiangjun; Zhang,Lei; Bai,Dan; Meng,Yujun; Wang,Jingyi

doi:10.3892/etm.2018.6451

LncRNA MEG3 overexpression inhibits the development of diabetic retinopathy by regulating TGF‑β1 and VEGF

Authors:
- Daning Zhang
- Haixiang Qin
- Ying Leng
- Xiangjun Li
- Lei Zhang
- Dan Bai
- Yujun Meng
- Jingyi Wang
View Affiliations

Affiliations: Department of Ophthalmology, Affiliated Hospital of Beihua University, Jilin 132011, P.R. China, Department of Legal Medical Experts, Public Security Bureau of Jilin City, Jilin 132011, P.R. China
Published online on: July 17, 2018 https://doi.org/10.3892/etm.2018.6451
Pages: 2337-2342

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In view of the high incidence of diabetic retinopathy and the functionality of long non‑coding RNA (lncRNA) maternally expressed gene 3 (MEG3) in different disease models, the present study aimed to investigate the role of MEG3 in diabetic retinopathy. In the study, patients with diabetic retinopathy, diabetic patients without retinopathy as well as healthy people were included. Fasting blood was extracted from each participant. Serum MEG3 levels were detected by everse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and serum vascular endothelial growth factor (VEGF) and transforming growth factor‑β1 (TGF‑β1) levels were detected by ELISA. Also, the effects of high glucose treatment on the expression of MEG3 and VEGF and the effects of MEG3 overexpression on expression of VEGF and TGF‑β1 in high glucose‑treated ARPE‑19 cells were detected by RT‑qPCR and western blot analysis to determine the mRNA and protein levels, respectively. It was indicated that serum levels of MEG3 were significantly lower, while the serum levels of VEGF and TGF‑β1 were significantly higher in patients with diabetic retinopathy and diabetic patients without retinopathy compared with the healthy controls. Furthermore, slight differences were found between patients with diabetic retinopathy and diabetic patients without retinopathy; however, these differences were not significant. The findings indicated that high glucose upregulated the expression of VEGF mRNA and downregulated the expression of MEG3, MEG3 overexpression reduced the increased expression levels of VEGF and TGF‑β1 induced by high glucose treatment. Therefore, it was concluded that lncRNA MEG3 overexpression may inhibit the development of diabetic retinopathy by inhibiting TGF‑β1 and VEGF expression.

View Figures

View References

1	Imamura F, O'Connor L, Ye Z, Mursu J, Hayashino Y, Bhupathiraju SN and Forouhi NG: Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: Systematic review, meta-analysis, and estimation of population attributable fraction. BMJ. 351:h35762015. View Article : Google Scholar : PubMed/NCBI
2	Nathan DM; DCCT/EDIC Research Group, : The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Overview. Diabetes Care. 37:9–16. 2014. View Article : Google Scholar : PubMed/NCBI
3	Leasher JL, Bourne RRA, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, Pesudovs K, Price H, White RA, Wong TY, et al: Global estimates on the number of people blind or visually impaired by diabetic retinopathy: A meta-analysis from 1990 to 2010. Diabetes Care. 39:1643–1649. 2016. View Article : Google Scholar : PubMed/NCBI
4	Kertes PJ and Johnson TM: Evidence-based eye care. Lippincott Williams & Wilkins; Philadelphia, PA: 2007
5	Tapp RJ, Shaw JE, Harper CA, de Courten MP, Balkau B, McCarty DJ, Taylor HR, Welborn TA and Zimmet PZ; AusDiab Study Group, : The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care. 26:1731–1737. 2003. View Article : Google Scholar : PubMed/NCBI
6	Perkel JM: Visiting ‘noncodarnia’. Biotechniques. 54:301, 303–304. 2013. View Article : Google Scholar
7	Hung T and Chang HY: Long noncoding RNA in genome regulation: prospects and mechanisms. RNA Biol. 7:582–585. 2010. View Article : Google Scholar : PubMed/NCBI
8	Yang G, Lu X and Yuan L: LncRNA: A link between RNA and cancer. Biochim Biophys Acta. 1839:1097–1109. 2014. View Article : Google Scholar : PubMed/NCBI
9	Kumarswamy R, Bauters C, Volkmann I, Maury F, Fetisch J, Holzmann A, Lemesle G, de Groote P, Pinet F and Thum T: Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res. 114:1569–1575. 2014. View Article : Google Scholar : PubMed/NCBI
10	Jaé N and Dimmeler S: Long noncoding RNAs in diabetic retinopathy. Circ Res. 116:1104–1106. 2015. View Article : Google Scholar : PubMed/NCBI
11	Qin R, Chen Z, Ding Y, Hao J, Hu J and Guo F: Long non-coding RNA MEG3 inhibits the proliferation of cervical carcinoma cells through the induction of cell cycle arrest and apoptosis. Neoplasma. 60:486–492. 2013. View Article : Google Scholar : PubMed/NCBI
12	Zhou Y, Zhang X and Klibanski A: MEG3 noncoding RNA: A tumor suppressor. J Mol Endocrinol. 48:R45–R53. 2012. View Article : Google Scholar : PubMed/NCBI
13	Ha H, Yu MR and Lee HB: High glucose-induced PKC activation mediates TGF-beta 1 and fibronectin synthesis by peritoneal mesothelial cells. Kidney Int. 59:463–470. 2001. View Article : Google Scholar : PubMed/NCBI
14	Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U and Shaw JE: Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 103:137–149. 2014. View Article : Google Scholar : PubMed/NCBI
15	Lopez-Galvez MI, Lavado FM and Pastor JC: Diabetic retinopathy: An overview. Handbook of Nutrition, Diet and the Eye. Academic Press; New York, NY: pp. 41–51. 2014, View Article : Google Scholar
16	Thomas AA, Feng B and Chakrabarti S: ANRIL: A Regulator of VEGF in Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 58:470–480. 2017. View Article : Google Scholar : PubMed/NCBI
17	Liu J, Li Q, Zhang KS, Hu B, Niu X, Zhou SM, Li SG, Luo YP, Wang Y and Deng ZF: Downregulation of the long non-coding RNA Meg3 promotes angiogenesis after ischemic brain injury by activating notch signaling. Mol Neurobiol. 54:8179–8190. 2017. View Article : Google Scholar : PubMed/NCBI
18	Simó R, Sundstrom JM and Antonetti DA: Ocular anti-VEGF therapy for diabetic retinopathy: The role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care. 37:893–899. 2014. View Article : Google Scholar : PubMed/NCBI
19	Goldfarb S and Ziyadeh FN: TGF-beta: A crucial component of the pathogenesis of diabetic nephropathy. Trans Am Clin Climatol Assoc. 112:27–33. 2001.PubMed/NCBI
20	Su W, Xie W, Shang Q and Su B: The long noncoding RNA MEG3 is downregulated and inversely associated with VEGF levels in osteoarthritis. Biomed Res Int. 2015:3568932015. View Article : Google Scholar : PubMed/NCBI
21	Mondal T, Subhash S, Vaid R, Enroth S, Uday S, Reinius B, Mitra S, Mohammed A, James AR, Hoberg E, et al: MEG3 long noncoding RNA regulates the TGF-β pathway genes through formation of RNA-DNA triplex structures. Nat Commun. 6:77432015. View Article : Google Scholar : PubMed/NCBI